A phase III, double-blind, placebocontrolled study was performed to examine the safety and efficacy of ramosetron in cancer patients with cisplatin-induced nausea/vomiting. Patients were divided into two groups: group R received 0.3 mg ramosetron intravenously and group P received placebo. Eightyeight patients were enrolled, 44 in each group; 84 (43 in group R, 41 in group P) were included in the clinical efficacy analysis and 86 (44 in group R, 42 in group P) in the safety analysis.
Introduction
The anti-cancer drug cisplatin (CDDP) shows remarkable anti-tumour effects against various malignancies. Of its adverse reactions, nausea and/or vomiting are extremely common and are far more severe than those caused by other traditional anti-cancer drugs. 1 Nausea and vomiting lead to symptoms that are considered to be dose-limiting factors in CDDP therapy, such as anorexia, generalized malaise and electrolyte abnormalities. 1 -7 One mechanism by which anti-cancer drugs (including CDDP) induce nausea/ vomiting involves 5-HT 3 receptors of the afferent vagus nerve; 8, 9 consequently, the anti-emetic properties of 5-HT 3 receptor antagonists, such as ramosetron (Nasea ® , Yamanouchi Pharmaceutical Co. Ltd, Tokyo, Japan), are being investigated. Preliminary experiments confirmed that ramosetron has potent anti-emetic effects, 10 -13 and in one phase II study we confirmed that ≤ 0.3 mg ramosetron, given as a single intravenous dose, was highly efficacious. 14 Following these results, we performed a double-blind, placebo-controlled study to evaluate the clinical usefulness of ramosetron against nausea and vomiting in cancer patients receiving CDDP therapy.
Patients and methods

INCLUSION/EXCLUSION CRITERIA
The study was performed in hospitalized male and female adult cancer patients at 32 institutions. All patients had received CDDP, given alone in a single dose of ≥ 50 mg/m 2 or concomitantly with other anticancer drugs, and experienced nausea and/or vomiting (including retching) afterwards.
Patients with severe complications (e.g. cardiac, renal and hepatic diseases); complications of diseases that could cause vomiting (e.g. gastrointestinal tract obstruction and active peptic ulcers); diseases that could cause vomiting (e.g. brain tumour, brain metastases and epilepsy); those who had received drugs that affect the CNS or gastrointestinal system within 24 h of CDDP administration (e.g. other anti-emetics, adrenocorticoids and anti-psychotics); those who had received CDDP three or more times prior to the study, or who had not experienced nausea or vomiting 24 h after receiving CDDP previously; those due to receive radiotherapy during the study; pregnant or possibly pregnant women; and patients otherwise considered ineligible were excluded from the study. Drugs to treat complications were permitted at the investigator's discretion.
Patients were withdrawn if ramosetron or placebo administration produced no change or exacerbated symptoms, if severe adverse reactions or complications occurred, or at the patient's request. When patients discontinued for any reason, the clinical efficacy of the study drug was evaluated at the time of discontinuation, and the date, time and reason(s) for withdrawal recorded. Investigators noted whether additional doses of ramosetron were administered after discontinuation.
All patients provided informed written or oral consent prior to participation in the study. The study conformed to the general requirements of the Declaration of Helsinki (updated Hong Kong, 1989).
TREATMENT
The dose of 0.3 mg ramosetron was chosen following results of a dose-determining study. 14 Study injections were allocated randomly to patients in a double-blind manner, and independent tests were undertaken to confirm their eligibility as investigational drugs. Each patient was randomized to receive 0.3 mg ramosetron (group R) or placebo (group P), and both agents were indistinguishable in appearance.
Vials of 0.3 mg ramosetron or placebo were administered intravenously as a bolus injection over a 1-min period to patients when CDDPinduced nausea/vomiting was observed. When nausea/vomiting was not suppressed after the first agent was administered, the investigator could discontinue the patient from the trial and administer 0.3 mg ramosetron intravenously, regardless of whether active agent or placebo had been given on the first occasion.
OBSERVATIONS
Patients' initials, medical record number, sex, age, height, body weight, body surface area, Eastern Co-operative Oncology Group (ECOG) performance status, 15 underlying disease (primary/metastatic lesions), present illness, past history and complications were recorded at enrolment. Prior surgery, radiotherapy, anti-cancer drugs and antiemetics, and the time of onset and frequency of any nausea and/or vomiting were noted.
The time, date, dose and solution of CDDP administered were recorded. Where applicable, the name, time, dose, date of administration, doses of other anti-cancer drugs and hydration treatments administered were also recorded.
Following CDDP administration, the times of onset of nausea/vomiting and subsequent ramosetron/placebo administration were recorded. The severity of nausea was evaluated every 6 h until 24 h after treatment administration, according to the following scale: 0 point, no symptoms; 1 point, mild nausea (patient tolerates solid foods and fluids); 2 points, moderate nausea (patient tolerates fluids but not solid foods); 3 points, severe nausea (patient cannot take solid foods or fluids). Grades of nausea during the 0 -6-h and 0 -24-h intervals after CDDP administration were then calculated from accumulated points. Finally, grades of nausea classified as A, B or C were assigned as follows: A: 0 -1 and 0 -4 points; B: 2 and 5 -8 points; and C: 3 and 9 -12 points in the 0 -6-h and 0 -24-h periods, respectively. The number of vomiting episodes following ramosetron or placebo administration was recorded.
After administration of ramosetron or placebo, eating and drinking patterns observed 24 h after CDDP administration were compared with baseline patterns, and evaluated as almost no change; about onehalf intake; about one-third or less intake; and almost no food intake.
When any accessory symptom occurred or was exacerbated, the symptom, time and date of occurrence, duration, severity (mild, moderate or severe), treatment and outcome were recorded. Patients with accessory symptoms were monitored until symptoms disappeared.
Standard laboratory tests (haematology, blood biochemistries, urinalysis) were performed before and 24 h after ramosetron or placebo administration. Body temperature, blood pressure and pulse rate were measured before and 24 h after administration of ramosetron or placebo and patients with abnormal measurements were monitored. All adverse events were recorded.
STATISTICAL ANALYSIS
Data were analysed under the guidance of the primary author. Parameters analysed included the severity of nausea, number of vomiting episodes and severity of anorexia. According to the handling of patients determined by the evaluation committee, data on parameters such as patient background, baseline conditions, efficacy and safety were included selectively. Differences between the ramosetron and placebo groups were analysed for efficacy and safety according to the characteristics of the data. The Mann-Whitney U-test, χ 2 -test and Fisher's direct probability method were used according to the characteristics of the data, with a significance level of P < 0.05.
Results
Eighty-eight patients were enrolled in the study and assigned to the groups. Eighty-six patients (44 in group R, 42 in group P) were included in the safety evaluation and 84 in the clinical efficacy evaluation (43 and 41 patients, respectively). Two patients in group P were excluded from all analyses because of multiple doses and intra-muscular administration of the study drug. Two patients (one in each group) were excluded from the clinical efficacy evaluation because ramosetron or placebo was given before CDDP therapy and nausea/vomiting occurred; their data were included only in the safety evaluation. Table 1 shows background characteristics of patients included in the clinical efficacy evaluation. No significant differences were found between the groups concerning sex, age, primary lesions, metastatic status, ECOG performance status, previous chemotherapy, occurrence of nausea/vomiting immediately before ramosetron or placebo administration, dose/ history of CDDP therapy and number of anticancer drugs used concomitantly with CDDP.
According to the criteria for the clinical efficacy evaluation, nausea severity was evaluated as mild (grade A) in 28 (65.1%) patients in group R and four (9.8%) patients in group P during the period 6 h postadministration of ramosetron or placebo (P < 0.001; Table 2 ). Over the 24-h study period, 23 (53.5%) patients in group R and five (12.2%) patients in group P had grade A nausea (P < 0.001).
Changes in the number of vomiting episodes after ramosetron or placebo administration are shown in Table 3 . No vomiting occurred during the 24-h period after administration in 15 (34.9%) patients in group R and in two (4.9%) patients in group P (P < 0.001). In 23 (53.5%) patients in group R and five (12.2%) patients in group P, the number of vomiting episodes was ≤ 2 (Table 3) . Table 4 shows the effects of the study agent on anorexia. Fifteen (36.6%) patients in group R and three (7.9%) in group P were evaluated as 'almost no change' or 'about one-half intake'. Disturbance in appetite was significantly more pronounced in the placebo group than in patients receiving ramosetron (P < 0.01). 
TABLE 1 (continued): Background characteristics of 84 patients included in the evaluation of clinical efficacy of ramosetron (n = 43) versus placebo (n = 41) in the treatment of cisplatin (CDDP)-induced nausea and vomiting
Ramosetron for cisplatin-induced nausea/vomiting
The only adverse reaction reported that was possibly related to ramosetron was a 'hot feeling in the head' described by one patient. This symptom occurred 3 h 50 min post-administration and was resolved 2 h after application of an ice pack.
Of the 86 patients included in the safety evaluation, abnormal laboratory values were observed in three patients (two in group R, one in group P). An increase in white blood cell count was observed in one group P patient (from 5300 to 15 300 cells/ml). In group R, one patient showed an increase in total bilirubin (from 1.2 to 1.9 mg/dl) and the other showed increases in alkaline phosphatase (from 278 to 340 IU/l) and γ-glutamyl transpeptidase (from 53 to 96 IU/l).
Discussion
Before the potential anti-emetic usage of 5-HT 3 receptor antagonists emerged for patients receiving anti-cancer drugs such as CDDP, nausea and vomiting treatment normally included concomitant high-dose dopamine D 2 -receptor antagonists. 16 -23 These drugs did not produce sufficient anti-emetic effects and there were concerns regarding adverse reactions, such as: extrapyramidal disorder, including stiffness of extremities, associated with metoclopramide; 24 decreased immune response due to decreases in natural killer activity of peripheral lymphocytes with adrenocorticoids; 25 and sleepiness and amnesia with minor tranquillizers. 26, 27 We confirmed in a previous dose-determining study that the 5-HT 3 receptor antagonist ramosetron showed anti-emetic effects at a single intravenous dose of 0.3 mg, with no safety concerns. 14 We found no bias in patient background between groups in the clinical efficacy evaluation, therefore we compared and examined the clinical usefulness of ramosetron and placebo. In the efficacy examinations, objective indices (nausea severity and number of vomiting episodes) were used. The grade of nausea between 0 and 24 h was evaluated as A (no or mild nausea) in 53.5% (23/43) of patients in group R and 12.2% (five of 41) in group P. In group R, 53.5% (23/43) of patients experienced two or fewer episodes of vomiting over the 24-h period, while vomiting was suppressed in only 12.2% (five of 41) of patients in group P. Thus we concluded that ramosetron was an effective inhibitory agent of CDDP-induced nausea and/or vomiting.
Ramosetron was considered useful in allowing patients to eat earlier after cancer In the evaluation of safety, an adverse reaction occurred in only one patient in group R and was categorized as a slight problem. Abnormal changes in laboratory values were observed in two patients in group R and one in group P. Of these, the transient increase in total bilirubin observed in one group R patient was probably related to ramosetron administration. It was impossible to judge whether changes observed in the other two patients were related to the study agent or anti-cancer drugs. All abnormal changes were mild and of no clinical significance.
These results demonstrate that 0.3 mg ramosetron given intravenously inhibited CDDP-induced nausea and/or vomiting effectively. In patients unresponsive to this dose, approximately 50% may be expected to respond to a second 0.3-mg dose with no safety concerns arising.
